This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Whelan, T. J. Articles by Pritchard, K. I. Search for Related Content PubMed PubMed Citation Articles by Whelan, T. J. Articles by Pritchard, K. I.

Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues

Authors' Affiliations: ¹ McMaster University, Hamilton, Ontario, Canada and ² Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada

Requests for reprints: Kathleen I. Pritchard, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. Phone: 416-480-4616; Fax: 416-480-6002; E-mail: kathy.pritchard{at}sw.ca.

Purpose: To review the health-related quality of life (QOL) of women treated with adjuvant hormonal therapy.

Experimental Design: To review the limited QOL data from randomized trials of tamoxifen versus placebo and ovarian ablation versus none. To discuss QOL results from randomized trials of aromatase inhibitors compared with tamoxifen or placebo for adjuvant therapy of postmenopausal women with estrogen receptor–positive and/or progesterone receptor–positive breast cancer.

Results: QOL is generally good in up to 3 years of follow-up with either tamoxifen or aromatase inhibitors. Vasomotor and sexual complaints remain problematic, however, in only a small proportion of women. There are fewer data regarding the QOL effects of ovarian ablation, which may nonetheless be more substantial.

Conclusion: Tamoxifen and aromatase inhibitors cause specific vasomotor or gynecologic symptoms, which may affect sexual function. However, clinical benefits of these agents are generally achieved without major detrimental effect on overall QOL.